In a move that serves as a high-stakes vote of confidence in the European life sciences sector, the Netherlands-based venture capital firm Forbion announced on October 6, 2026, that it has successfully closed two new funds totaling 2.3 billion euros—approximately $2.6 billion. This record-breaking raise arrives at a critical juncture, providing a much-needed injection of "dry powder" into an industry that has recently struggled to keep pace with the hyper-competitive ecosystems of the United States and China.
Forbion’s latest achievement, which significantly exceeded the firm’s initial fundraising targets, underscores its status as the preeminent life sciences venture firm in Europe. With 7.5 billion euros now under management, the firm is positioning itself to be the primary bridge between groundbreaking European academic research and the global pharmaceutical marketplace.
The Financial Backbone: A Breakdown of the Funds
The capital was raised across two distinct vehicles: Forbion Growth Opportunities IV and Forbion Ventures Fund VIII. These funds are designed to provide a comprehensive life-cycle investment strategy. According to the firm, the combined capacity of these funds allows Forbion to participate in the growth of up to 30 early-to-mid-stage biotechnology startups.
The strategy is already in motion. The firm has confirmed that it has begun deploying capital, with recent investments in high-potential ventures such as Sling Therapeutics and Solstice Oncology. These selections reflect Forbion’s established preference for companies with high-impact, transformative potential in areas like oncology, immunology, and rare disease.
The backing for these funds came from a prestigious coalition of institutional investors, including Dutch pension giants MN and PGGM, the Kauffman Foundation, Germany’s KfW Capital, and major pharmaceutical player Eli Lilly. This diverse base of limited partners highlights the strategic importance of Forbion’s portfolio to both financial institutions looking for growth and corporate entities seeking to stay ahead of the innovation curve.
A Proven Track Record: From Lab Bench to IPO
Since its inception, Forbion has been more than a mere financier; it has functioned as a company builder. The firm has supported 142 companies throughout its history, with 21 of its portfolio companies successfully ushering medical products or drugs to the commercial market.
Forbion’s investment philosophy centers on identifying "de-risked" science—technologies that have moved beyond basic discovery into the more rigorous phases of preclinical and clinical validation. This approach has led to a string of high-profile successes in recent years, drawing the attention of major "Big Pharma" acquirers. Notable exits include:
- Capstan Therapeutics: Acquired by AbbVie for its pioneering in vivo cell therapy platform.
- Mariana Oncology: A major acquisition by Novartis to bolster its radiopharmaceutical pipeline.
- Aiolos Bio: Purchased by GSK to secure access to innovative asthma treatments.
Beyond acquisitions, Forbion has successfully shepherded its portfolio companies through the public markets. Firms such as MapLight Therapeutics have navigated the challenging IPO landscape, demonstrating that, despite broader market volatility, high-quality, Forbion-backed assets remain attractive to public investors. With at least 55 investments announced since the start of 2022, Forbion remains one of the most prolific and active investors in the global biopharmaceutical sector.
Chronology of European Biotech’s Competitive Struggle
To understand the significance of this $2.6 billion raise, one must look at the trajectory of the European biotech market over the last decade.
- 2020-2022: The "Golden Era" of biotech funding saw record-breaking capital inflows during the COVID-19 pandemic. Europe experienced a surge in investor interest, but growth remained heavily concentrated in hubs like Switzerland, the U.K., and the Netherlands.
- 2023-2024: As global interest rates rose and the venture capital market cooled, the disparity between European and American funding began to widen. While the U.S. benefited from deep-rooted, risk-tolerant capital markets, European firms faced increased regulatory friction.
- 2024: Forbion’s previous $2.2 billion raise provided a temporary buffer, but market indicators began showing signs of a "capital drain."
- 2026 (Present): The European biotech industry has reached a point of vocal frustration, with industry leaders openly challenging government policy regarding the continent’s competitiveness.
The Institutional Crisis: Why Europe is Falling Behind
The success of Forbion stands in stark contrast to the broader malaise affecting the European life sciences industry. In September 2026, just weeks before Forbion’s announcement, nine prominent European board chairs issued an open letter that sent shockwaves through the Brussels policy circles.
These leaders, representing some of the most influential companies in the sector, argued that Europe is failing to leverage its scientific prowess. Their central thesis was that Europe has consistently treated the pharmaceutical industry "as a cost to suppress rather than one of the best investments a government can make."
The report highlighted three primary factors contributing to this decline:
- Regulatory Rigidity: A bureaucratic landscape that slows down clinical trial initiation compared to the streamlined, albeit aggressive, processes seen in China.
- Clinical Trial Migration: Due to the aforementioned regulatory hurdles, pharmaceutical companies are increasingly moving their pivotal R&D phases to North America or Asia.
- Fragmented Capital Markets: Unlike the U.S., which possesses a unified capital market for biotech, Europe’s fragmented nature makes it difficult for companies to scale from "startup" to "multinational" without moving their operations or listing on the NASDAQ.
The executives warned that "Europe’s alarm bells are ringing," and without systemic reform, the continent risks becoming a secondary market for drug development rather than a leader in innovation.
Official Responses and Strategic Implications
Sander Slootweg, co-founder and managing partner at Forbion, acknowledged the current market tension during his announcement. "Our successful fundraising gives us significant dry powder in a market characterized by a general shortage of capital," he stated. His remarks suggest that Forbion is not just filling a gap; they are intentionally positioning themselves as a stabilizer in a volatile environment.
Industry analysts suggest that Forbion’s ability to raise such a massive sum serves as a litmus test for the European sector. If a firm of this caliber can secure $2.6 billion, it proves that the assets and innovation are present; the problem lies in the environment that nurtures them.
For the startups that will eventually receive this capital, the implications are profound. With Forbion’s backing, these companies gain more than just liquidity; they gain access to a network of expertise, a history of successful exits, and the political weight of a firm that is now managing 7.5 billion euros.
The Path Forward: Can Innovation Outpace Policy?
As Forbion begins to deploy its new funds, the broader European biotech industry finds itself in a race. On one side is the undeniable talent and academic excellence that has long defined the European scientific tradition. On the other side is the structural inertia of European regulatory policy.
The success of Forbion’s Funds VIII and IV will likely serve as a catalyst for other venture firms. However, as the nine board chairs noted in their letter, private capital alone cannot reverse the decline. There is a growing demand for a "European Biotech Act" that would mirror the support systems found in China and the United States, focusing on R&D tax credits, streamlined clinical trials, and a harmonized European health data space.
For now, Forbion remains a beacon of optimism. In a landscape defined by caution and consolidation, the firm’s $2.6 billion commitment is a loud, clear message to the global markets: Europe’s biotech industry is not ready to yield. The capital is there, the science is waiting, and for the next 30 companies that secure Forbion’s backing, the future may look significantly brighter than the headlines would suggest.
About the Author
